Biologics use in Indian psoriasis patients
The biologics currently in use for psoriasis in India are etanercept, infliximab and recently introduced itolizumab and secukinumab. Biosimilars, expected to play a significant role in psoriasis management in future, have also been available for the last few years. Patients with psoriasis may be con...
Saved in:
Main Authors: | Murlidhar Rajagopalan (Author), Asit Mital (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2016-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A case of cutaneous T-cell lymphoma, masquerading as psoriasis, was given etanercept and secukinumab: Emphasizing the need for biopsy confirmation before starting biologics
by: Abhishek De, et al.
Published: (2017) -
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
by: Rajagopalan M, et al.
Published: (2021) -
Biologicals in the treatment of psoriasis: The Indian perspective
by: Ajit B Janagond, et al.
Published: (2017) -
Fumarates in dermatology
by: Murlidhar Rajagopalan
Published: (2011) -
Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
by: Kiran Godse, et al.
Published: (2016)